Literature DB >> 2677038

Androgens and estrogens in postmenopausal insulin-treated diabetic women.

H Nyholm1, H Djursing, C Hagen, T Agner, P Bennett, B Svenstrup.   

Abstract

Diabetic women may have an increased risk of developing endometrial carcinoma. Ovarian and adrenal activity seem to be factors in the genesis of this cancer. We have measured serum sex hormone-binding globulin (SHBG), free and bound fractions of estrogens and androgens, and gonadotropins in 20 consecutive postmenopausal insulin-treated diabetic women and 16 normal postmenopausal women. The diabetics were nonketoacidotic, without nephropathy and without proliferative retinopathy. The groups were comparable regarding age and percent ideal body weight. The diabetic group had significantly increased serum levels of estrone (P less than 0.001), estrone sulfate (P less than 0.05), 17 beta-estradiol (P less than 0.02), and SHBG (P less than 0.001). Levels of testosterone, delta 4-androstenedione, and dehydroepiandrosterone sulfate tended to be higher (not significantly) in the diabetics. FSH and LH levels were similar in the two groups, while serum PRL was significantly lower in the diabetic group (P less than 0.02). The hormonal changes in the diabetics were not related to control of the diabetes. We conclude that total estrogen levels are increased in postmenopausal women with insulin-treated diabetes mellitus. High SHBG levels in these patients tend to keep the free fractions of sex hormones within normal limits.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2677038     DOI: 10.1210/jcem-69-5-946

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  13 in total

Review 1.  Novel applications of COX-2 inhibitors, metformin, and statins for the primary chemoprevention of breast cancer.

Authors:  Darren Micallef; Sarah Micallef; Pierre Schembri-Wismayer; Jean Calleja-Agius
Journal:  J Turk Ger Gynecol Assoc       Date:  2016-12-01

2.  Relationship between diabetes and risk of second primary contralateral breast cancer.

Authors:  Christopher I Li; Janet R Daling; Mei-Tzu C Tang; Kathleen E Malone
Journal:  Breast Cancer Res Treat       Date:  2010-07-13       Impact factor: 4.872

3.  Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women.

Authors:  Julie R Palmer; Nelsy Castro-Webb; Kimberly Bertrand; Traci N Bethea; Gerald V Denis
Journal:  Cancer Res       Date:  2017-11-15       Impact factor: 12.701

4.  Oestradiol levels may differ between premenopausal women, ages 18-50, with type 1 diabetes and matched controls.

Authors:  Lina Saleh Hassan; Rebecca S Monson; Kirstie K Danielson
Journal:  Diabetes Metab Res Rev       Date:  2016-06-30       Impact factor: 4.876

Review 5.  The endocrine system in diabetes mellitus.

Authors:  Hisham Alrefai; Hisham Allababidi; Shiri Levy; Joseph Levy
Journal:  Endocrine       Date:  2002-07       Impact factor: 3.633

Review 6.  Nutrition, hormones, and breast cancer: is insulin the missing link?

Authors:  R Kaaks
Journal:  Cancer Causes Control       Date:  1996-11       Impact factor: 2.506

7.  Sex hormone-binding globulin and testosterone in individuals with childhood diabetes.

Authors:  Kirstie K Danielson; Melinda L Drum; Rebecca B Lipton
Journal:  Diabetes Care       Date:  2008-03-17       Impact factor: 19.112

Review 8.  The prognostic outcome of 'type 2 diabetes mellitus and breast cancer' association pivots on hypoxia-hyperglycemia axis.

Authors:  Ilhaam Ayaz Durrani; Attya Bhatti; Peter John
Journal:  Cancer Cell Int       Date:  2021-07-05       Impact factor: 5.722

9.  A case-control study of diabetes mellitus and cancer risk.

Authors:  C La Vecchia; E Negri; S Franceschi; B D'Avanzo; P Boyle
Journal:  Br J Cancer       Date:  1994-11       Impact factor: 7.640

10.  Cancer incidence and mortality in patients with insulin-treated diabetes: a UK cohort study.

Authors:  A J Swerdlow; S P Laing; Z Qiao; S D Slater; A C Burden; J L Botha; N R Waugh; A D Morris; W Gatling; E A Gale; C C Patterson; H Keen
Journal:  Br J Cancer       Date:  2005-06-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.